Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models
about
The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulationGlutamatergic substrates of drug addiction and alcoholismPotential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonistSelective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in miceMetabotropic glutamate receptors as novel targets for anxiety and stress disordersThe age of anxiety: role of animal models of anxiolytic action in drug discovery.Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups.Metabotropic glutamate receptors: novel targets for pain relief.Emerging targets for the treatment of depressive disorder.Therapeutic potential of metabotropic glutamate receptor modulators.Are compounds acting at metabotropic glutamate receptors the answer to treating depression?Differential modulation of ethanol-induced sedation and hypnosis by metabotropic glutamate receptor antagonists in C57BL/6J mice.The metabotropic glutamate 2/3 receptor agonist LY379268 induces anxiety-like behavior at the highest dose tested in two rat models of anxiety.Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsGlutamate-based anxiolytic ligands in clinical trials.Ecdysone-based system for controlled inducible expression of metabotropic glutamate receptor subtypes 2, 5, and 8.Inhibition of morphine withdrawal by the NMDA receptor antagonist MK-801 in rat is age-dependent.Morphine tolerance and reward but not expression of morphine dependence are inhibited by the selective glutamate carboxypeptidase II (GCP II, NAALADase) inhibitor, 2-PMPA.In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling.Group II and III metabotropic glutamate receptors suppress excitatory synaptic transmission in the dorsolateral bed nucleus of the stria terminalis.Anxiolytic activity of the MGLU2/3 receptor agonist LY354740 on the elevated plus maze is associated with the suppression of stress-induced c-Fos in the hippocampus and increases in c-Fos induction in several other stress-sensitive brain regions.Broad spectrum efficacy with LY2969822, an oral prodrug of metabotropic glutamate 2/3 receptor agonist LY2934747, in rodent pain models.
P2860
Q24613593-CFFFED3A-ABDB-454C-9649-C145CD236E7CQ24648924-62E362E8-A03F-4165-93E2-CFA40F5FB78CQ24673932-1B636F92-BE2B-4C75-ADFD-CF2B92DF2AA7Q24674933-37CCCBFA-017B-43C4-A97F-FDAFE37700C2Q28303826-46523700-0F2E-4FB7-BAB8-7D674E8AA42BQ30462832-D22CA5D1-E88B-426B-A0EE-F6F66605F7FFQ30486159-2131E174-A23E-4D7A-A8B0-51EC20B07426Q33509127-B45145C3-B80A-4062-A13C-F4103A982624Q35050432-FFF25F35-6619-46EB-BB30-31DBDA943AEBQ35778704-BAB1C39F-681D-4445-A69C-5681B14C272AQ36654331-5995FF14-8F2C-4040-AC9E-9892D83F074FQ36871587-6BCE988D-8BD3-4E33-BDA9-18C675057EABQ37151763-7C3D55A8-BC73-4994-B605-B8B8E046A988Q37183072-079C7B13-7544-4E8C-BBD2-1BB801F8C9C9Q38110306-C0A902C8-E8CF-436B-AD82-419CE1656F48Q40360459-8A6EABC0-B8D5-4FA1-A803-9D2D192738E2Q43579998-FEFE5DBD-9D4B-4BA7-99DD-C22FD43EF168Q44357517-D48A8CE3-CDB4-4AE5-9253-2C9E3B667050Q44686787-61509E04-C239-40A0-80E4-8B6027EE54EDQ46423982-A64C60B9-E1F1-490F-B260-038B97EACF1FQ48106927-AEEAB4BA-75B3-48DF-9C6E-003EF7D4777EQ48318347-8560B8C6-321D-4807-8AB5-00E2719645C1
P2860
Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Potential anti-anxiety, anti-a ...... ptors agonist in animal models
@ast
Potential anti-anxiety, anti-a ...... ptors agonist in animal models
@en
Potential anti-anxiety, anti-a ...... ptors agonist in animal models
@nl
type
label
Potential anti-anxiety, anti-a ...... ptors agonist in animal models
@ast
Potential anti-anxiety, anti-a ...... ptors agonist in animal models
@en
Potential anti-anxiety, anti-a ...... ptors agonist in animal models
@nl
prefLabel
Potential anti-anxiety, anti-a ...... ptors agonist in animal models
@ast
Potential anti-anxiety, anti-a ...... ptors agonist in animal models
@en
Potential anti-anxiety, anti-a ...... ptors agonist in animal models
@nl
P2093
P50
P1433
P1476
Potential anti-anxiety, anti-a ...... ptors agonist in animal models
@en
P2093
A Kłodzińska
E Chojnacka-Wójcik
P304
P356
10.1016/S0028-3908(99)00066-0
P407
P577
1999-12-01T00:00:00Z